Sugi Predict

Sugi Predict / Compounds / SCHEMBL6319767

SCHEMBL6319767

SCHEMBL6319767

CNC(=O)C(CNC(=O)C(CNC(=O)/C=C/CC(C)(C)NC(=O)OC(C)(C)C)Cc1ccc2ccccc2c1)Cc1ccccc1F

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 8/20 0.42
▸ CTSS P25774 2/20 0.42
▸ CTSK P43235 2/20 0.42
▸ CTSB P07858 1/20 0.42
▸ GHSR Q92847 4/20 0.37
▸ PTPN2 P17706 7/20 0.34
▸ CDC25B P30305 7/20 0.34
▸ PTPN6 P29350 3/20 0.34
▸ FCER2 P06734 1/20 0.34
▸ CYP3A4 P08684 2/20 0.33
▸ CYP2D6 P10635 2/20 0.33
▸ SLC6A2 P23975 2/20 0.33
▸ SLC6A4 P31645 2/20 0.33
▸ SLC6A3 Q01959 2/20 0.33
▸ KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319778 1.00 PTPN1 (0.42) PTPN1CTSSCTSKCTSBGHSR
SCHEMBL6323483 0.92 CTSS (0.44) PTPN1CTSSCTSKCTSBGHSR
SCHEMBL6323474 0.92 CTSS (0.44) PTPN1CTSSCTSKCTSBGHSR
SCHEMBL6318159 0.79 PTPN1 (0.40) PTPN1CTSSCTSKCTSBGHSR
SCHEMBL6318319 0.78 GHSR (0.54) PTPN1CTSSCTSKCTSBGHSR
SCHEMBL6317984 0.77 CTSS (0.52) PTPN1CTSSCTSKCTSBFCER2
SCHEMBL6318001 0.74 PTPN1 (0.40) PTPN1CTSSCTSKCTSBGHSR
SCHEMBL6319720 0.71 GHSR (0.56) CTSSCTSKCTSBGHSR
SCHEMBL6320792 0.71 CTSS (0.41) PTPN1CTSSCTSKCTSBGHSR
SCHEMBL6320865 0.71 CTSS (0.40) CTSSCTSKCTSBGHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 — — US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 — — US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 — — US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 — — US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 — — US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 — — EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 PTPN1 4478/4885CTSS 2319/4885CTSK 1324/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR PTPN1 4506/4885CTSS 2636/4885CTSK 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.